ApoB (apolipoprotein B) is a structural protein tag attached to each plaque-forming lipoprotein particle in your blood, including LDL, VLDL, IDL, and Lp(a). Across 15 discordance studies covering 593,354 adults, heart attack risk tracks the number of ApoB particles in your arteries instead of the weight of cholesterol inside them (LDL-C). Fishtown Medicine aims for an ApoB between 60 and 80 mg/dL for general prevention, and 60 mg/dL or under when Lp(a) is 70 nmol/L or higher, when a close relative had heart disease before age 55, or when plaque appears on coronary imaging.
TL;DR: Standard cholesterol panels measure LDL-C, which is the weight of cholesterol carried inside your blood particles. ApoB counts the total number of plaque-forming particles themselves. Across 15 large studies of nearly 600,000 adults, when LDL-C and ApoB disagree, heart attack risk follows ApoB every time. At Fishtown Medicine, our preventive target is 60 to 80 mg/dL for general prevention, and 60 mg/dL or under if you have high Lp(a) (>= 70 nmol/L), a family history of heart disease before age 55, or plaque on a coronary scan. If your ApoB is above target, follow these four steps:
- Check the full particle and metabolic picture: Run ApoB alongside a one-time Lp(a) in nmol/L, fasting insulin, triglycerides, hs-CRP, and TSH (since slow thyroid function slows liver particle clearance).
- Pull the nutrition and metabolic levers first: Aim for 30 to 50 grams of daily soluble fiber (oats, beans, psyllium), cap saturated fat, and reverse insulin resistance. Those steps can trim ApoB by 10% to 20%.
- Image the arteries when you near a decision line: Use a Coronary Calcium Score (CAC) or a Coronary CT Angiogram (CCTA) to see whether soft or calcified plaque is present.
- Use combination therapy instead of maxing out a single statin: Doubling a statin dose adds only ~4% to 6% extra lowering while raising muscle and blood-sugar side effects. Pairing a low-dose hydrophilic statin (rosuvastatin 5 to 10 mg) with ezetimibe (10 mg), or using muscle-sparing bempedoic acid or a PCSK9 inhibitor, brings ApoB to target with far fewer side effects.
If your routine cholesterol panel came back green and your doctor told you everything looked fine, you may still be carrying far more arterial traffic than that printout showed. Roughly half of adults admitted to the hospital with a first heart attack have a "normal" LDL cholesterol on a standard lipid panel.12
Standard panels miss that risk because they weigh the cargo inside your cholesterol particles instead of counting the particles hitting your artery walls. This guide covers how ApoB fixes that blind spot, what five landmark cohorts show when LDL-C and ApoB disagree, and why modern combination therapy reaches target more gently than high-dose statin monotherapy.
Why is ApoB more accurate than standard LDL cholesterol?
ApoB is more accurate than standard LDL cholesterol because each plaque-forming particle in your blood carries one apolipoprotein B (ApoB) molecule on its shell, making an ApoB blood test a direct particle count.12 Standard LDL-C, by contrast, estimates the total weight (mass) of cholesterol tucked inside LDL particles.
Picture your coronary arteries as the Vine Street Expressway (I-676) at rush hour:
- The cholesterol weight on your standard panel (LDL-C) is the number of passengers riding inside the cars.
- ApoB is the total number of cars on the highway.
Traffic jams and crashes into the guardrail depend on how many cars are on the road, regardless of whether each car holds four passengers or one.1 Inside a human artery, plaque forms when an ApoB-carrying particle crosses the inner lining, gets trapped in the vessel wall, and triggers an immune reaction.13
Measuring ApoB also captures the entire fleet of plaque-forming particles at once. A standard LDL-C reading misses VLDL, IDL, remnant cholesterol particles, and Lipoprotein(a), whereas ApoB counts all of them.23 Once you know your total ApoB count, UK Biobank data (n = 389,529) show that particle size subclasses (small dense LDL vs large buoyant LDL) and triglyceride ratios add no extra prediction.34
What happens when LDL cholesterol and ApoB disagree (Discordance)?
When your LDL cholesterol looks normal on paper but your ApoB count is high (a mismatch called discordance), your heart attack risk follows ApoB instead of LDL-C.25 In a 2025 review of all 15 discordance studies covering 593,354 adults, ApoB beat LDL-C in 9 out of 9 comparisons.5
Five landmark cohorts show how large that gap is in everyday patients:
| Cohort Study | Population | Key Finding When ApoB and LDL-C Disagree |
|---|---|---|
| Women's Health Study (Mora et al., Circulation 2014) | 27,533 women followed for 17 to 20 years | Nearly 1 in 5 women (18.9%) had discordant numbers. Women with below-average LDL-C but high ApoB had a 2.48-fold higher risk of coronary events (HR 2.48). Women with high LDL-C but low ApoB had a 66% lower risk (HR 0.34).8 |
| UK Biobank (Marston 2022 & Welsh 2019) | 389,529 primary-prevention adults | Each standard-deviation rise in ApoB increased heart attack risk by 38% (HR 1.38). Among discordant adults, only ApoB predicted events (HR 1.23), while LDL-C did not.39 |
| INTERHEART (Sniderman et al., 2012) | 9,345 heart attack cases & 12,120 controls across 52 countries | Adults with cholesterol-depleted particles (high ApoB relative to cholesterol mass) had 58% higher odds of a heart attack (OR 1.58) across all ethnic groups.7 |
| Framingham Offspring (Pencina et al., 2015) | 2,966 adults | Each standard-deviation rise in ApoB above what LDL-C predicted raised future coronary heart disease risk by 26% (HR 1.26).6 |
| CARDIA Young Adult Study (Wilkins et al., JACC 2016) | Young adults starting at mean age 25 | High ApoB with normal LDL-C at age 25 (even with normal BMI, fasting glucose, and triglycerides) predicted coronary artery calcium 25 years later.10 |
Who is most likely to have a high ApoB hidden behind a "normal" LDL?
Discordance happens whenever your liver packs less cholesterol into each particle and sends out a larger fleet of small, cholesterol-depleted particles. We see this pattern most often in four groups:
- Anyone with early insulin resistance or visceral fat: Even when your HbA1c is normal, high fasting insulin (> 7 uIU/mL) or triglycerides above 100 to 150 mg/dL causes the liver to overproduce VLDL particles. The CETP enzyme then swaps triglycerides for cholesterol, leaving behind swarms of small LDL particles.111 The 2026 ACC/AHA Dyslipidemia Guideline flags triglycerides >= 150 mg/dL as a direct trigger to measure ApoB.11
- "Skinny-fat" or lean insulin-resistant adults: You do not need a high BMI to have discordance. In a study of 411,125 Korean adults, metabolic health drove high ApoB discordance more strongly than body weight, and lean insulin-resistant adults carried heavy particle overload.12
- South Asian adults: In the UCSF MASALA study, South Asian adults developed insulin resistance, high Lp(a), and coronary plaque roughly a decade earlier and at lower body weights than European-descent adults.21 That makes early ApoB and Lp(a) testing essential. See our South Asian health playbook.
- Young adults in their 20s and 30s: As the CARDIA study proved, a high ApoB in your 20s silently lays down plaque decades before a standard 10-year risk calculator wakes up.10
What ApoB targets does Fishtown Medicine aim for?
Fishtown Medicine sets your ApoB target in two tiers based on your risk profile, well below the standard commercial lab flag of 100 mg/dL:
- General Prevention Target (60 to 80 mg/dL): For adults without coronary plaque, without a premature family history of heart disease, and with a low inherited Lp(a) (< 70 nmol/L).
- Higher-Risk Preventive Target (60 mg/dL or under): For anyone with an Lp(a) of 70 nmol/L or above, a family history of cardiac or vascular disease before age 55, or calcified or soft plaque on coronary imaging (CAC > 0 or CCTA).1113 In patients with established cardiovascular disease, international guidelines (2025 ESC/EAS and 2026 ACC/AHA) set ApoB goals at < 55 to 65 mg/dL, and PCSK9 trials safely reached 39 to 45 mg/dL with no lower-limit safety signal.111319
Before starting medication for a high ApoB, we check three reversible confounders that can push ApoB up on their own:
- Sluggish thyroid function (TSH, Free T4, Free T3): Thyroid hormone controls how many LDL receptors your liver puts on its surface. Even mild hypothyroidism slows particle clearance and raises ApoB.
- Under-fueling in lean endurance athletes (RED-S): Chronic calorie deficits in high-volume runners or cyclists can spike LDL and ApoB alongside low fasting insulin (<= 3 uIU/mL).
- High saturated-fat or ketogenic diets: Heavy intake of butter, ghee, coconut oil, or fatty meats reduces liver LDL receptors and sends ApoB climbing.
Why does combination therapy beat doubling a statin dose (The Rule of 6)?
When nutrition and metabolic changes do not bring ApoB into range, the smartest move is combining two low-dose medications that work on different pathways instead of pushing one statin to its maximum dose.1617
In traditional primary care, if rosuvastatin 10 mg or atorvastatin 20 mg leaves your ApoB too high, the reflex is to double the statin dose to 20 mg, then 40 mg, then 80 mg. Pharmacology trials show why that works poorly:
1. The "Rule of 6": Tiny extra particle drops for every statin doubling
Statins have a steep log-linear dose curve. Roughly two-thirds of a statin's total ApoB-lowering power happens at one-quarter of the maximum dose (5 mg of rosuvastatin drops ApoB by 35% to 45%).14 Across the VOYAGER meta-analysis (n = 32,258) and Cochrane reviews, doubling a statin dose adds only 4.4% to 6% extra reduction in LDL-C and ApoB.14 Doubling a statin three times in a row buys you only ~14% more lowering.
2. High-intensity statin doses carry disproportionate blood-sugar and muscle trade-offs
While the particle-lowering benefit flattens out at the top of the statin dose range, side effects climb with dose intensity:
- Blood sugar and new-onset diabetes (CTT Collaboration 2024): In randomized trial data, low- to moderate-intensity statins carried a tiny excess of new diabetes (0.12% per year, RR 1.10). High-intensity statins jumped to a 36% relative increase (RR 1.36, 1.27% per year excess).15 Read our breakdown on whether statins cause diabetes.
- Muscle aches (CTT Collaboration 2022, n = 123,940): High-intensity statins carried a higher relative rate of muscle symptoms (RR 1.08) than moderate-intensity statins (RR 1.03), while blinded trials confirm that roughly 14 out of 15 aches on low or moderate statins also happen on placebo.22
3. The RACING and IMPROVE-IT Trials: Why low/moderate statin + ezetimibe wins
Your body gets cholesterol from two places: your liver makes it (the pathway statins slow down) and your gut absorbs it via the NPC1L1 transporter (the pathway ezetimibe blocks). When you take a high-dose statin alone, your gut compensates by absorbing more cholesterol. Adding a 10 mg tablet of ezetimibe shuts that back door and adds 15% to 20% extra ApoB lowering (equal to three statin dose-doublings) with placebo-level side effects.1617
In the RACING randomized trial (Kim et al., Lancet 2022, n = 3,780 patients followed for 3 years), researchers compared moderate-dose rosuvastatin (10 mg) + ezetimibe (10 mg) against high-dose rosuvastatin (20 mg) alone:16
- More patients hit target: 72% of the combination group reached strict lipid goals at 3 years versus 58% of the high-dose statin group (median LDL-C 58 vs 66 mg/dL).
- Fewer patients had to quit or cut their dose: Intolerance discontinuations or dose cuts dropped nearly in half (4.8% vs 8.2%, p < 0.0001), with fewer muscle symptoms (1.1% vs 1.9%).
- Matched heart protection: Three-year cardiovascular death, major coronary events, and stroke were non-inferior (9.1% vs 9.9%, HR 0.95). That builds on the IMPROVE-IT trial (Cannon et al., NEJM 2015, n = 18,144), which proved that adding ezetimibe to a statin lowers hard cardiovascular events (HR 0.936, and HR 0.85 in diabetes).1617
What if you cannot tolerate statins at all, or need deeper ApoB lowering?
Modern lipidology gives us three proven non-statin tools beyond ezetimibe when statins cause muscle aches or when high Lp(a) or plaque calls for deeper ApoB clearance:
| Medication Class | How It Works | Typical ApoB / LDL Drop | Landmark Trial & Clinical Sweet Spot |
|---|---|---|---|
| Low-Dose Rosuvastatin (5-10 mg) + Ezetimibe (10 mg) | Slows liver synthesis + blocks gut NPC1L1 absorption | ~50% to 55% combined | RACING (Lancet 2022) & IMPROVE-IT (NEJM 2015): First-line dual oral plan; beats high-dose statin monotherapy on target rate (72% vs 58%) and tolerability.1617 |
| Bempedoic Acid (Nexletol, 180 mg oral) (+ Ezetimibe in Nexlizet) | Inhibits ATP-citrate lyase in the liver; prodrug is never activated in skeletal muscle | ~15% to 21% solo (~38% paired with ezetimibe) | CLEAR Outcomes (NEJM 2023, n = 13,970): Cut 4-point MACE by 13% (HR 0.87) and heart attacks by 23% (HR 0.77) (HR 0.70 in primary prevention). Showed zero excess muscle aches (5.6% vs 6.8% placebo) and zero new diabetes (check baseline uric acid, as gout rose 3.1% vs 2.1%).18 |
| PCSK9 Antibodies (Evolocumab / Alirocumab, q2w-q4w pen) | Blocks PCSK9 from destroying liver LDL receptors so the liver clears particles rapidly | ~50% to 60% (plus 19% to 30% Lp(a) drop) | FOURIER (n = 27,564, HR 0.80) & ODYSSEY Outcomes (n = 18,924, HR 0.85): Deepest ApoB drop; FOURIER-OLE showed a 20% all-cause mortality reduction over 5 years in patients without prior MI/stroke.1920 |
| Inclisiran (Leqvio, twice-yearly injection) | siRNA that silences liver PCSK9 mRNA production for 6 months per dose | ~42% ApoB (~50% LDL-C) | ORION-9/10/11: Twice-yearly maintenance dosing; dedicated outcomes readout (ORION-4, n = 16,124) is underway and expected around 2027.13 |
For a deeper walkthrough of how we sequence these options if you have had statin side effects, read Beyond Statins: Other Ways to Lower Cholesterol and ApoB.
Actionable Steps in Philly
Use this 4-step playbook to find and fix your particle risk:
- Add ApoB and a one-time Lp(a) to your next blood draw: If your standard panel only lists Total Cholesterol, HDL, Triglycerides, and calculated LDL-C, ask for ApoB (~$20 to $40 cash) and Lp(a) in nmol/L so you know your particle count.
- Match your ApoB target to your risk tier: Aim for 60 to 80 mg/dL for general prevention, or 60 mg/dL and under if your Lp(a) is >= 70 nmol/L, if a close relative had heart disease before age 55, or if coronary imaging shows plaque.
- See the vessel wall directly when you near a decision threshold: A standard calcium score (CAC) misses non-calcified soft plaque in adults under 55.4 When knowing whether soft plaque is present would change your plan, we order a standard Coronary CT Angiogram (CCTA) (~$400 to $450 cash). We reserve the $1,500+ Cleerly AI overlay for cases where multi-year serial plaque volume tracking is planned.
- Choose low-dose combination therapy over statin dose-escalation: When lifestyle levers (30 to 50 g/day soluble fiber, lower saturated fat, and reversing insulin resistance) leave ApoB above target, pair a low-dose hydrophilic statin (rosuvastatin 5 mg) with ezetimibe 10 mg or use liver-specific bempedoic acid. That clears particles without high-dose statin side effects.
Guidance from the Clinic
Key Takeaways
- ApoB counts every plaque-forming particle (LDL, VLDL, IDL, Lp(a)), whereas standard LDL-C only weighs the cholesterol cargo inside them.12
- Across 15 discordance studies (n = 593,354), risk tracks ApoB whenever it disagrees with LDL-C - including a 2.48x higher coronary event rate in women with "normal" LDL-C but high ApoB.58
- Fishtown Medicine targets an ApoB of 60 to 80 mg/dL for general prevention, and 60 mg/dL or under for higher risk (Lp(a) >= 70 nmol/L, family history of heart disease under age 55, or plaque on imaging).
- Doubling a statin dose (The Rule of 6) adds only ~4.4% to 6% extra lowering while high-intensity statin doses raise new-onset diabetes risk by +36% (RR 1.36).1415
- Low-dose combination therapy (rosuvastatin 5-10 mg + ezetimibe 10 mg in RACING) gets more patients to target (72% vs 58%) and cuts intolerance discontinuations nearly in half (4.8% vs 8.2%).16
- For statin-intolerant or high-risk patients, muscle-sparing bempedoic acid (CLEAR Outcomes) and PCSK9 therapies (FOURIER, ODYSSEY) provide proven event reduction without skeletal muscle toxicity.1819
Scientific References
- Glavinovic T, Thanassoulis G, de Graaf J, et al. "Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk." Journal of the American Heart Association (JAHA). 2022;11(20):e025858.
- Sniderman AD, Navar AM, Thanassoulis G. "Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over." JAMA Cardiology. 2022;7(3):257-258.
- Marston NA, Giugliano RP, Melloni GEM, et al. "Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content." JAMA Cardiology. 2022;7(3):250-256.
- Morze J, Melloni GEM, Wittenbecher C, et al. "ApoB-containing Lipoproteins: Count, Type, Size, and Risk of Coronary Artery Disease." European Heart Journal. 2025;46(18):1720-1731.
- Sehayek D, Cole J, Bjornson E, et al. "ApoB, LDL-C, and Non-HDL-C as Markers of Cardiovascular Risk: A Systematic Review of Discordance Studies." Journal of Clinical Lipidology. 2025;19(4):612-624.
- Pencina MJ, D'Agostino RB, Zdrojewski T, et al. "Apolipoprotein B Improves Risk Assessment of Future Coronary Heart Disease in the Framingham Heart Study Beyond LDL-C and Non-HDL-C." European Journal of Preventive Cardiology. 2015;22(10):1321-1327.
- Sniderman AD, Islam S, Yusuf S, McQueen MJ. "Discordance Analysis of Apolipoprotein B and Non-High Density Lipoprotein Cholesterol as Markers of Cardiovascular Risk in the INTERHEART Study." Atherosclerosis. 2012;225(2):444-449.
- Mora S, Buring JE, Ridker PM. "Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events" (Women's Health Study). Circulation. 2014;129(5):553-561.
- Welsh C, Celis-Morales CA, Brown R, et al. "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data From UK Biobank." Circulation. 2019;140(7):542-552.
- Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. "Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study." Journal of the American College of Cardiology (JACC). 2016;67(2):193-201.
- Blumenthal RS, Morris PB, et al. "2026 ACC/AHA Guideline on the Management of Dyslipidemia." Circulation. 2026;153(12):e450-e520.
- Kim JA, Park MS, Cho EH, et al. "Associations of Metabolic Health and Obesity With Apolipoprotein B and Low-Density Lipoprotein Cholesterol Discordance in a Large Korean Cohort." Journal of Clinical Lipidology. 2025;19(6):901-911.
- De Oliveira-Gomes D, Joshi PH, Peterson ED, et al. "Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice." Circulation. 2024;149(25):1995-2010.
- Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. "Meta-Analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (From VOYAGER)." The American Journal of Cardiology. 2010;105(1):69-76.
- Cholesterol Treatment Trialists' (CTT) Collaboration. "Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia in Large-Scale Randomised Blinded Statin Trials: An Individual Participant Data Meta-Analysis." The Lancet Diabetes & Endocrinology. 2024;12(5):306-319.
- Kim BK, Hong SJ, Lee YJ, et al. "Long-Term Efficacy and Safety of Moderate-Intensity Statin With Ezetimibe Combination Therapy Versus High-Intensity Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease (RACING): A Randomised, Open-Label, Non-Inferiority Trial." The Lancet. 2022;400(10349):380-390.
- Cannon CP, Blazing MA, Giugliano RP, et al. "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes" (IMPROVE-IT). New England Journal of Medicine. 2015;372(25):2387-2397.
- Nissen SE, Lincoff AM, Brennan D, et al. "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients" (CLEAR Outcomes). New England Journal of Medicine. 2023;388(15):1353-1364.
- Sabatine MS, Giugliano RP, Keech AC, et al. "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease" (FOURIER). New England Journal of Medicine. 2017;376(18):1713-1722.
- Ference BA, Ginsberg HN, Graham I, et al. "Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel." European Heart Journal. 2017;38(32):2459-2472.
- Kanaya AM, Kandula N, Herrington D, et al. "Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: Objectives, Methods, and Cohort Description." Clinical Cardiology. 2013;36(12):713-720.
- Cholesterol Treatment Trialists' (CTT) Collaboration. "Effect of Statin Therapy on Muscle Symptoms: An Individual Participant Data Meta-Analysis of Large-Scale, Randomised, Double-Blind Trials." The Lancet. 2022;400(10355):832-845.
Related Articles:
Related at Fishtown Medicine
- 9-System Biomarker Reference Guide: Optimal vs Standard Lab Ranges - side-by-side optimal targets for ApoB, Lp(a), LDL-C, triglycerides, non-HDL, and all 9 systems
- Borderline Cholesterol: How ApoB, Lp(a), and Blood Pressure Change the Plan - a patient case where 3 unmeasured numbers turned "recheck in a year" into a plan
- Stroke Prevention in Philadelphia - the 2024 AHA/ASA guideline applied across BP, GLP-1, diet, CRF, and insulin resistance
- Lp(a): The 'Widowmaker' Genetic Risk - the genetic cholesterol particle that standard panels miss, present in 1 in 5 adults
- Lp(a) and Cholesterol - why you can have perfect cholesterol and still be at high risk
- ED and Cardiovascular Risk - erectile dysfunction as the earliest warning sign of vascular disease
- Longevity Medicine in Philadelphia - where ApoB fits in a full healthspan plan
- Metabolic Health in Philadelphia - insulin resistance and ApoB travel together
- High Triglycerides: What Your Number Means and What To Do - high triglycerides are often the visible clue that ApoB is elevated too
- Your Calcium Score Is High. Now What? - the workup that turns a scary calcium score into a plan, starting with ApoB
- Health for South Asians - why heart disease comes a decade early, and the ApoB and Lp(a) workup that catches it in time
- Why Isn't My HDL Going Up? - the lipid marker that lags behind, and why the pattern matters more than the number
- What Is a Preventive Cardiologist? - who should lead your heart-attack prevention
- Heart Disease in Women - why women's heart risk is different, and often missed
- Beyond Statins: Other Ways to Lower ApoB - ezetimibe, bempedoic acid, and PCSK9 inhibitors
- What Happens When You Stop a Statin - how quickly ApoB and risk climb back once treatment stops
- Should You Take a Daily Aspirin? - where aspirin still fits once ApoB is being treated properly
- Lowering Lp(a): The First Drugs That Can - the trials working toward a treatment aimed at Lp(a) itself
- The Advanced Tests Your Doctor Isn't Ordering - the fuller panel behind ApoB
- Macular Degeneration and AREDS2 - the eye shares the vascular health ApoB tracks
- High Fibrinogen: What It Means for Your Heart - a risk marker that ApoB outranks as a causal, treatable lever
- Lp-PLA2 (the PLAC Test): What It Means for Your Heart - a vascular inflammation marker that should send you back to ApoB
- Remnant Cholesterol: The Risk Hiding in Your Standard Panel - the extra cholesterol stream ApoB already counts, and how to find it for free
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





